1.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 8 to 70
Sponsor: Other
Protocol IDs: Lithium-5010, NCT01669369
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 382, NCT00691236
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 40 and over
Sponsor: Other
Protocol IDs: ISG/OS-2, 2011-001659-36, NCT01459484
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 21
Sponsor: Other
Protocol IDs: CCLG-EPSSG-NRSTS-2005, EU-20620, EUDRACT-2005-001139-31, UKCCSG-CTA-21275/0215/001/0001, CCLG-EpSSG-STS-2006-03, NCT00334854
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 5 to 50
Sponsor: Other
Protocol IDs: CDR0000543987, FRE-FNCLCC-SARCOME-09-0603, FRE-FNCLCC-OS-2006, NOVARTIS-FRE-FNCLCC-SARCOME-09, CHUGAI-FRE-FNCLCC-SARCOME-09-0, EU-20729, EUDRACT-2006-00337727, NOVARTIS-FRE-FNCLCC-SARCOME-09-0603, CHUGAI-FRE-FNCLCC-SARCOME-09-0603, SARCOME 09/0603, NCT00470223
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BM016, NCT01091883
|
|
7.
|
Phase: Phase III
Type: Health services research, Treatment
Status: Approved-not yet active
Age: 6 to 18
Sponsor: Other
Protocol IDs: 1000018144, NCT01176981
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-154, NCT01223248
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TH-CR-406/SARC021, NCT01440088
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7040-J081-301, NCT01677624
|
|
11.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 8 to 65
Sponsor: Other
Protocol IDs: 381, NCT00689195
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 6 to 120
Sponsor: Other
Protocol IDs: HITHD-01, NCT01005043
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AVF4761s, 200911736, NCT01106872
|
|
14.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01412, 10-049, CDR0000680558, MSKCC-10049, U01CA069856, 8406, NCT01154452
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 3 to 75
Sponsor: Other
Protocol IDs: NDV-HUJ-HMO-CTIL, NCT01174537
|
|
16.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 20
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: 100220, IND 59,056, NCT01222780
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Other
Protocol IDs: 2010-0700, NCT01590069
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: RTSARC, NCT00186992
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: Other
Protocol IDs: NAVE-CYCLO, NCT00180947
|
|
21.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, Other, NCT00592293
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: IOSI-RO0402, RO0402, NCT00637637
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: PIP, CSET 2003/1053, NCT00181025
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 74
Sponsor: Other
Protocol IDs: SARC012, D8180C00039, NCT00752206
|
Mobile | Español